Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies

Patent 11466094 was granted and assigned to Genentech on October, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo